Delix Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 24

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $100M

  • Investors
  • 49

Delix Therapeutics General Information

Description

Developer of neuroplastogen therapeutics designed to treat neuropsychiatric and neurological conditions by promoting rapid and sustained neuroplasticity in targeted brain circuits. The company offers oral, non-hallucinogenic compounds that promote selective structural and functional neuroplasticity, enabling patients with difficult-to-treat brain disorders to access fast-acting, long-lasting treatments that can be administered outside clinical settings.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 20 Authors Road
  • Concord, MA 01742
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Corporate Office
  • 20 Authors Road
  • Concord, MA 01742
  • United States
+1 (617)

Delix Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Delix Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series C) 09-Nov-2026 $100M Completed Clinical Trials - Phase 2
8. Later Stage VC (Series B) 15-Dec-2025 Completed Clinical Trials - Phase 2
7. Grant 04-Jun-2024 Completed Clinical Trials - Phase 1
6. Grant 01-Dec-2023 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series B) 10-Jan-2022 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series A) 03-Sep-2021 Completed Pre-Clinical Trials
3. Seed Round 01-Jul-2020 Completed Pre-Clinical Trials
2. Corporate 06-Mar-2020 $500K $500K Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2019 Completed Pre-Clinical Trials
To view Delix Therapeutics’s complete valuation and funding history, request access »

Delix Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view Delix Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Delix Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of neuroplastogen therapeutics designed to treat neuropsychiatric and neurological conditions by promoting rap
Drug Discovery
Concord, MA
24 As of 2026

Bedminster, NJ
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Delix Therapeutics Competitors (12)

One of Delix Therapeutics’s 12 competitors is Intracellular Therapies, a Formerly VC-backed company based in Bedminster, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intracellular Therapies Formerly VC-backed Bedminster, NJ
Gilgamesh Pharma Venture Capital-Backed New York, NY
Neurocrine Biosciences Formerly VC-backed San Diego, CA
MapLight Therapeutics Formerly VC-backed Burlington, MA
Relmada Therapeutics Formerly VC-backed Coral Gables, FL
You’re viewing 5 of 12 competitors. Get the full list »

Delix Therapeutics Patents

Delix Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026072561-A1 Methods of using n-substituted indole neuroplastogens Pending 25-Sep-2024
WO-2026072584-A1 Methods of using phenoxy and benzyloxy substituted neuroplastogens Pending 25-Sep-2024
WO-2026072510-A1 Methods of identifying effective amounts of plastogens Pending 24-Sep-2024
WO-2026035553-A1 Patient specific methods of treating neuropsychiatric disorders with non-hallucinogenic tryptamines Pending 05-Aug-2024
EP-4827835-A1 Mixed serotonin receptor binders for treatment of psychotic disorders Pending 22-Dec-2023 A61K45/06
To view Delix Therapeutics’s complete patent history, request access »

Delix Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Delix Therapeutics Investors (49)

Investor Name Investor Type Holding Investor Since Participating Rounds
Adage Capital Management Hedge Fund Minority
Hamilton Square Partners Management PE/Buyout Minority
Johnson & Johnson JJDC Corporate Venture Capital Minority
SV Health Investors PE/Buyout Minority
Vestal Point Capital Hedge Fund Minority
You’re viewing 5 of 49 investors. Get the full list »

Delix Therapeutics FAQs

  • When was Delix Therapeutics founded?

    Delix Therapeutics was founded in 2019.

  • Where is Delix Therapeutics headquartered?

    Delix Therapeutics is headquartered in Concord, MA.

  • What is the size of Delix Therapeutics?

    Delix Therapeutics has 24 total employees.

  • What industry is Delix Therapeutics in?

    Delix Therapeutics’s primary industry is Drug Discovery.

  • Is Delix Therapeutics a private or public company?

    Delix Therapeutics is a Private company.

  • What is Delix Therapeutics’s current revenue?

    The current revenue for Delix Therapeutics is .

  • How much funding has Delix Therapeutics raised over time?

    Delix Therapeutics has raised $208M.

  • Who are Delix Therapeutics’s investors?

    Adage Capital Management, Hamilton Square Partners Management, Johnson & Johnson JJDC, SV Health Investors, and Vestal Point Capital are 5 of 49 investors who have invested in Delix Therapeutics.

  • Who are Delix Therapeutics’s competitors?

    Intracellular Therapies, Gilgamesh Pharma, Neurocrine Biosciences, MapLight Therapeutics, and Relmada Therapeutics are some of the 12 competitors of Delix Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process